Parkinson`s medication Safinamide 50 mg & 100 mg successfully launched in the UK 🚀
For patients living with Parkinson’s disease, continuity of treatment matters every day. In the UK alone, around 166.000 people are currently living with Parkinson’s – with newly diagnosed every 20 minutes. Bringing affordable therapies to the market is not only about a successful launch, but about ensuring patients can continue to access the medicines they rely on. 💊
This milestone reflects a remarkable effort across our teams, working together under significant time pressure to bring this in-house developed and manufactured product to patients together with our partner in the UK
At TiefenbacherGroup, this launch is part of our broader ambition to continue pioneering healthcare through better therapies, better access, and better affordability for patients worldwide. 🌍
